hiv infections

Summary

Summary: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).

Top Publications

  1. pmc Prevention of HIV-1 infection with early antiretroviral therapy
    Myron S Cohen
    University of North Carolina at Chapel Hill, Institute for Global Health and Infectious Diseases, Suite 2115, Bioinformatics Bldg, 130 Mason Farm Rd, CB 7030, Chapel Hill, NC 27599, USA
    N Engl J Med 365:493-505. 2011
  2. pmc Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    Quarraisha Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Durban 4013, South Africa
    Science 329:1168-74. 2010
  3. pmc Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
  4. doi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
  5. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
  6. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
  7. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
  8. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
  9. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
  10. pmc Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial
    Bertran Auvert
    Hopital Ambroise Pare, Assitance Publique Hôpitaux de Paris, Boulogne, France
    PLoS Med 2:e298. 2005

Research Grants

  1. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2002
  2. BIOPTERIN, CATECHOLAMINES, & NO IN REGULATING APOPTOSIS
    Robert Levine; Fiscal Year: 2002
  3. Preventing HIV and other STDs among drug-involved women
    Nabila El Bassel; Fiscal Year: 2005
  4. HIV/STI Prevention for Drug-Involved Couples
    Louisa Gilbert; Fiscal Year: 2008
  5. PARTNER ABUSE AND HIV IN WOMEN RECEIVING EMERGENCY CARE
    Nabila El Bassel; Fiscal Year: 2002
  6. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2009
  7. Intervention to Close Digital Divide in AIDS Care
    Seth Kalichman; Fiscal Year: 2004
  8. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2009
  9. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2008
  10. HIV TREATMENT ADHERENCE FOR PERSONS WITH LOW-LITERACY
    Seth Kalichman; Fiscal Year: 2002

Detail Information

Publications290 found, 100 shown here

  1. pmc Prevention of HIV-1 infection with early antiretroviral therapy
    Myron S Cohen
    University of North Carolina at Chapel Hill, Institute for Global Health and Infectious Diseases, Suite 2115, Bioinformatics Bldg, 130 Mason Farm Rd, CB 7030, Chapel Hill, NC 27599, USA
    N Engl J Med 365:493-505. 2011
    ..Antiretroviral therapy that reduces viral replication could limit the transmission of human immunodeficiency virus type 1 (HIV-1) in serodiscordant couples...
  2. pmc Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women
    Quarraisha Abdool Karim
    Centre for the AIDS Program of Research in South Africa CAPRISA, Durban 4013, South Africa
    Science 329:1168-74. 2010
    ..Tenofovir gel could potentially fill an important HIV prevention gap, especially for women unable to successfully negotiate mutual monogamy or condom use...
  3. pmc Preexposure chemoprophylaxis for HIV prevention in men who have sex with men
    Robert M Grant
    J David Gladstone Institutes, University of California at San Francisco, 1650 Owens St, San Francisco, CA 94158, USA
    N Engl J Med 363:2587-99. 2010
    ..Antiretroviral chemoprophylaxis before exposure is a promising approach for the prevention of human immunodeficiency virus (HIV) acquisition...
  4. doi Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand
    Supachai Rerks-Ngarm
    Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    N Engl J Med 361:2209-20. 2009
    ..The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control...
  5. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial
    Barton F Haynes
    Duke University Human Vaccine Institute and the Center for HIV AIDS Vaccine Immunology, Duke University School of Medicine, Durham, NC 27710, USA
    N Engl J Med 366:1275-86. 2012
    ..In the RV144 trial, the estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed a case-control analysis to identify antibody and cellular immune correlates of infection risk...
  6. pmc Broad neutralization coverage of HIV by multiple highly potent antibodies
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 477:466-70. 2011
    ....
  7. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  8. ncbi Microbial translocation is a cause of systemic immune activation in chronic HIV infection
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Med 12:1365-71. 2006
    ..These data establish a mechanism for chronic immune activation in the context of a compromised gastrointestinal mucosal surface and provide new directions for therapeutic interventions that modify the consequences of acute HIV infection...
  9. doi Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
    Stuart J D Neil
    Aaron Diamond AIDS Research Center and Laboratory of Retrovirology, The Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nature 451:425-30. 2008
    ..Vpu co-localized with CD317 and inhibited these effects. Inhibition of Vpu function and consequent mobilization of tetherin's antiviral activity is a potential therapeutic strategy in HIV/AIDS...
  10. pmc Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial
    Bertran Auvert
    Hopital Ambroise Pare, Assitance Publique Hôpitaux de Paris, Boulogne, France
    PLoS Med 2:e298. 2005
    ..Observational studies suggest that male circumcision may provide protection against HIV-1 infection. A randomized, controlled intervention trial was conducted in a general population of South Africa to test this hypothesis...
  11. doi Identification of host proteins required for HIV infection through a functional genomic screen
    Abraham L Brass
    Department of Genetics, Center for Genetics and Genomics, Brigham and Women s Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
    Science 319:921-6. 2008
    ..This effort illustrates the power with which RNA interference and forward genetics can be used to expose the dependencies of human pathogens such as HIV, and in so doing identify potential targets for therapy...
  12. pmc SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx
    Nadine Laguette
    Institut de Genetique Humaine, Laboratoire de Virologie Moleculaire, CNRS UPR1142, Montpellier 34000, France
    Nature 474:654-7. 2011
    ..Our results demonstrate that SAMHD1 is an antiretroviral protein expressed in cells of the myeloid lineage that inhibits an early step of the viral life cycle...
  13. ncbi Adherence to medication
    Lars Osterberg
    General Medicine Division, Veterans Affairs Palo Alto Health Care System, Palo Alto, California 94304, USA
    N Engl J Med 353:487-97. 2005
  14. ncbi Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial
    Ronald H Gray
    Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21215, USA
    Lancet 369:657-66. 2007
    ..Ecological and observational studies suggest that male circumcision reduces the risk of HIV acquisition in men. Our aim was to investigate the effect of male circumcision on HIV incidence in men...
  15. pmc Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein
    Kasia Hrecka
    Department of Molecular Biology and Microbiology, Case School of Medicine, Cleveland, Ohio 44106, USA
    Nature 474:658-61. 2011
    ....
  16. pmc Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1
    Xueling Wu
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Science 329:856-61. 2010
    ..Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design...
  17. pmc Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Science 333:1633-7. 2011
    ..Comparison of the crystal structure of one of the antibodies to the broadly neutralizing antibody VRC01 revealed conservation of the contacts to the HIV spike...
  18. ncbi Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial
    Robert C Bailey
    Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL 60612, USA
    Lancet 369:643-56. 2007
    ..Our aim was to determine whether male circumcision had a protective effect against HIV infection, and to assess safety and changes in sexual behaviour related to this intervention...
  19. ncbi 2011 update of the drug resistance mutations in HIV-1
    Victoria A Johnson
    Birmingham Veterans Affairs Medical Center and the University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA
    Top Antivir Med 19:156-64. 2011
    ..This November 2011 edition of the IAS-USA drug resistance mutations list updates the figures last published in December 2010 (Johnson VA et al, Top HIV Med, 2010;18:156-163)...
  20. pmc HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
    Michael R Betts
    Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Blood 107:4781-9. 2006
    ..Thus, rather than quantity or phenotype, the quality of the CD8(+) T-cell functional response serves as an immune correlate of HIV disease progression and a potential qualifying factor for evaluation of HIV vaccine efficacy...
  21. pmc The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
    Florencia Pereyra
    Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology MIT and Harvard, Boston, MA, USA
    Science 330:1551-7. 2010
    ..These results implicate the nature of the HLA-viral peptide interaction as the major factor modulating durable control of HIV infection...
  22. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  23. doi Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
    Reuben M Granich
    Department of HIV AIDS, WHO, Geneva, Switzerland
    Lancet 373:48-57. 2009
    ..We investigated a theoretical strategy of universal voluntary HIV testing and immediate treatment with ART, and examined the conditions under which the HIV epidemic could be driven towards elimination...
  24. pmc Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication
    Renate König
    Infectious and Inflammatory Disease Center, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Cell 135:49-60. 2008
    ..Taken together, the multiscale approach described here has uncovered multiprotein virus-host interactions that likely act in concert to facilitate the early steps of HIV-1 infection...
  25. doi Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial
    Richard T Lester
    Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya
    Lancet 376:1838-45. 2010
    ..We aimed to assess whether mobile phone communication between health-care workers and patients starting antiretroviral therapy in Kenya improved drug adherence and suppression of plasma HIV-1 RNA load...
  26. ncbi The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys
    Matthew Stremlau
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 427:848-53. 2004
    ..Our studies identify TRIM5alpha as a species-specific mediator of innate cellular resistance to HIV-1 and reveal host cell components that modulate the uncoating of a retroviral capsid...
  27. pmc Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    Susan P Buchbinder
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA, USA
    Lancet 372:1881-93. 2008
    ..The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels...
  28. pmc Plasma levels of soluble CD14 independently predict mortality in HIV infection
    Netanya G Sandler
    Human Immunology Section, Vaccine Research Center
    J Infect Dis 203:780-90. 2011
    ..The association of microbial translocation with clinical outcome remains unknown...
  29. pmc Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review
    Sydney Rosen
    Center for Global Health and Development, Boston University, Boston, Massachusetts, USA
    PLoS Med 8:e1001056. 2011
    ..We conducted a systematic review of pre-ART retention in care in Africa...
  30. pmc Global trends in molecular epidemiology of HIV-1 during 2000-2007
    Joris Hemelaar
    Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, UK
    AIDS 25:679-89. 2011
    ..To estimate the global and regional distribution of HIV-1 subtypes and recombinants between 2000 and 2007...
  31. doi Genome-scale RNAi screen for host factors required for HIV replication
    Honglin Zhou
    Department of Virus and Cell Biology, Merck and Co, Inc, West Point, PA 19486, USA
    Cell Host Microbe 4:495-504. 2008
    ..This study highlights both the power and shortcomings of large scale loss-of-function screens in discovering host-pathogen interactions...
  32. ncbi PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
    Cheryl L Day
    HIV Pathogenesis Programme, Doris Duke Medical Research Institute, University of KwaZulu Natal, Durban 4013, South Africa
    Nature 443:350-4. 2006
    ..Moreover, this pathway of reversible T-cell impairment provides a potential target for enhancing the function of exhausted T cells in chronic HIV infection...
  33. pmc HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors
    Robert K Heaton
    University of California, San Diego, CA, USA
    J Neurovirol 17:3-16. 2011
    ..Clinical trials targeting HAND prevention should specifically examine timing of ART initiation...
  34. pmc HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study
    R K Heaton
    University of California, San Diego, USA
    Neurology 75:2087-96. 2010
    ....
  35. doi Tuberculosis
    Stephen D Lawn
    The Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
    Lancet 378:57-72. 2011
    ....
  36. pmc Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders
    Cristian Pop-Eleches
    School of International and Public Affairs, Columbia University, New York, New York, USA
    AIDS 25:825-34. 2011
    ..This study tested the efficacy of short message service (SMS) reminders on adherence to ART among patients attending a rural clinic in Kenya...
  37. doi Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, Atlanta, Georgia, USA
    JAMA 304:321-33. 2010
    ....
  38. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  39. pmc The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein
    Nanette Van Damme
    The San Diego Department of Veterans Affairs Healthcare System, San Diego, CA 92161, USA
    Cell Host Microbe 3:245-52. 2008
    ....
  40. pmc HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
    Nicolas Chomont
    Laboratoire d Immunologie, Centre de Recherche du Centre Hospitalier de l Université de Montréal Saint Luc, Montreal, Quebec, Canada
    Nat Med 15:893-900. 2009
    ....
  41. pmc Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing
    Xueling Wu
    Vaccine Research Center, National Institutes of Health, Bethesda, MD 20892, USA
    Science 333:1593-602. 2011
    ....
  42. pmc Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
    Elena E Perez
    Abramson Family Cancer Research Institute, Department of Pathology and Laboratory Medicine, 421 Curie Blvd, Room 554, BRB II III, Philadelphia, Pennsylvania 19104 6160, USA
    Nat Biotechnol 26:808-16. 2008
    ..Thus adoptive transfer of ex vivo expanded CCR5 ZFN-modified autologous CD4(+) T cells in HIV patients is an attractive approach for the treatment of HIV-1 infection...
  43. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
    ..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
  44. doi Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies
    Marie Claude Boily
    Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College, London, UK
    Lancet Infect Dis 9:118-29. 2009
    ..Efforts are needed to better understand these differences and to quantify infectivity in low-income countries...
  45. pmc Inflammatory and coagulation biomarkers and mortality in patients with HIV infection
    Lewis H Kuller
    University of Pittsburgh, Pittsburgh, Pennsylvania, USA
    PLoS Med 5:e203. 2008
    ..We hypothesized that increased HIV-RNA levels following ART interruption induced activation of tissue factor pathways, thrombosis, and fibrinolysis...
  46. ncbi CD4+ count-guided interruption of antiretroviral treatment
    W M El-Sadr
    Division of Infectious Diseases, Harlem Hospital Center and Columbia University, New York, NY 10037, USA
    N Engl J Med 355:2283-96. 2006
    ..Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV)...
  47. doi The burden of non-communicable diseases in South Africa
    Bongani M Mayosi
    Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa
    Lancet 374:934-47. 2009
    ....
  48. pmc Antiretroviral prophylaxis for HIV prevention in heterosexual men and women
    Jared M Baeten
    Department of Global Health, University of Washington, Seattle, WA 98104, USA
    N Engl J Med 367:399-410. 2012
    ..Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations...
  49. pmc The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection
    Edward M Gardner
    Denver Public Health, Denver, Colorado, USA
    Clin Infect Dis 52:793-800. 2011
    ....
  50. doi Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis
    Suzanna Attia
    Institute of Social and Preventive Medicine, University of Bern, Switzerland
    AIDS 23:1397-404. 2009
    ..To synthesize the evidence on the risk of HIV transmission through unprotected sexual intercourse according to viral load and treatment with combination antiretroviral therapy (ART)...
  51. pmc HIV infection, inflammation, immunosenescence, and aging
    Steven G Deeks
    Department of Medicine, San Francisco General Hospital, University of California San Francisco, CA, USA
    Annu Rev Med 62:141-55. 2011
    ..Novel therapeutic strategies aimed at preventing or reversing these immunologic defects may be necessary if HIV-infected patients are to achieve normal life span...
  52. pmc Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis
    Deborah Donnell
    Statistical Center for HIV AIDS Research and Prevention and the Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Lancet 375:2092-8. 2010
    ..Initiation of antiretroviral therapy (ART) reduces plasma HIV-1 concentrations. We aimed to assess the effect of ART use by patients infected with HIV-1 on risk of transmission to their uninfected partners...
  53. pmc Effect of early versus deferred antiretroviral therapy for HIV on survival
    Mari M Kitahata
    University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359931, Seattle, WA 98104, USA
    N Engl J Med 360:1815-26. 2009
    ..The optimal time for the initiation of antiretroviral therapy for asymptomatic patients with human immunodeficiency virus (HIV) infection is uncertain...
  54. pmc Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review
    Matthew P Fox
    Center for Global Health and Development, Boston University, Boston, MA 02118, USA
    Trop Med Int Health 15:1-15. 2010
    ..To estimate the proportion of all-cause adult patient attrition from antiretroviral therapy (ART) programs in service delivery settings in sub-Saharan Africa through 36 months on treatment...
  55. pmc Estimated HIV incidence in the United States, 2006-2009
    Joseph Prejean
    Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America
    PLoS ONE 6:e17502. 2011
    The estimated number of new HIV infections in the United States reflects the leading edge of the epidemic. Previously, CDC estimated HIV incidence in the United States in 2006 as 56,300 (95% CI: 48,200-64,500)...
  56. doi Towards an improved investment approach for an effective response to HIV/AIDS
    Bernhard Schwartlander
    Joint United Nations Programme on HIV AIDS, Geneva, Switzerland
    Lancet 377:2031-41. 2011
    ..Implementation of the new investment framework would avert 12·2 million new HIV infections and 7·4 million deaths from AIDS between 2011 and 2020 compared with continuation of present approaches, and ..
  57. doi Effect of point-of-care CD4 cell count tests on retention of patients and rates of antiretroviral therapy initiation in primary health clinics: an observational cohort study
    Ilesh V Jani
    Instituto Nacional da Saúde, Maputo, Mozambique
    Lancet 378:1572-9. 2011
    ..We implemented point-of-care counting of CD4 cells in Mozambique and assessed the effect on loss to follow-up before immunological staging and treatment initiation...
  58. ncbi Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs
    Gary Marks
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention CDC, Atlanta, GA 30333, USA
    J Acquir Immune Defic Syndr 39:446-53. 2005
    ..To compare the prevalence of high-risk sexual behaviors in HIV persons aware of their serostatus with that in HIV persons unaware of their status in the United States and to discuss implications for HIV prevention programs...
  59. doi Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation
    Gero Hütter
    Department of Hematology, Oncology, and Transfusion Medicine, Campus Benjamin Franklin, Charite Universitatsmedizin Berlin, Germany
    N Engl J Med 360:692-8. 2009
    ..The patient remained without viral rebound 20 months after transplantation and discontinuation of antiretroviral therapy. This outcome demonstrates the critical role CCR5 plays in maintaining HIV-1 infection...
  60. pmc CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract
    Jason M Brenchley
    Human Immunology Section, Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, 40 Convent Dr, Room 3509, Bethesda, MD 20892, USA
    J Exp Med 200:749-59. 2004
    ....
  61. pmc Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study
    Julio S G Montaner
    British Columbia Centre for Excellence in HIV AIDS, Providence Health Care, Vancouver, BC, Canada
    Lancet 376:532-9. 2010
    ..We aimed to estimate the association between plasma HIV-1 viral load, HAART coverage, and number of new cases of HIV in the population of a Canadian province...
  62. pmc Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
    N M Archin
    The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Nature 487:482-5. 2012
    ....
  63. doi The challenge of finding a cure for HIV infection
    Douglas D Richman
    San Diego VA Healthcare System and University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0679, USA
    Science 323:1304-7. 2009
    ..This review discusses our current understanding of suppressive antiretroviral therapy, the latent viral reservoir, and the needs for and challenges of attacking this reservoir to achieve a cure...
  64. pmc Elevated risk for HIV infection among men who have sex with men in low- and middle-income countries 2000-2006: a systematic review
    Stefan Baral
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
    PLoS Med 4:e339. 2007
    ....
  65. pmc Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation
    Liang Shan
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Immunity 36:491-501. 2012
    ..These results demonstrate that stimulating HIV-1-specific CTLs prior to reactivating latent HIV-1 may be essential for successful eradication efforts and should be considered in future clinical trials...
  66. pmc Early antiretroviral therapy and mortality among HIV-infected infants
    Avy Violari
    Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
    N Engl J Med 359:2233-44. 2008
    ..We investigated antiretroviral-treatment strategies in the Children with HIV Early Antiretroviral Therapy (CHER) trial...
  67. doi Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy
    Alex Sigal
    Division of Biology, California Institute of Technology, Pasadena, California 91125, USA
    Nature 477:95-8. 2011
    ....
  68. doi Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel
    Melanie A Thompson
    AIDS Research Consortium of Atlanta, 131 Ponce de Leon Ave NE, Ste 130, Atlanta, GA 30308, USA
    JAMA 308:387-402. 2012
    ..New trial data and drug regimens that have become available in the last 2 years warrant an update to guidelines for antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected adults in resource-rich settings...
  69. ncbi Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA
    Gary Marks
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention CDC, Atlanta, Georgia 30333, USA
    AIDS 20:1447-50. 2006
    New HIV infections stem from people who are aware they are HIV positive (approximately 75% of infected persons in the USA) and those who are unaware of their HIV-positive status (approximately 25%).
  70. ncbi Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
    Matthias Egger
    Department of Social and Preventive Medicine, University of Bern, CH 3012 Bern, Switzerland
    Lancet 360:119-29. 2002
    ..The ART Cohort Collaboration, which includes 13 cohort studies from Europe and North America, was established to fill this knowledge gap...
  71. pmc Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
    Peter W Hunt
    Positive Health Program, San Francisco General Hospital, Bldg 80, Ward 84, 995 Potrero Ave, San Francisco, CA 94110, USA
    J Infect Dis 197:126-33. 2008
    ....
  72. pmc Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
    R Brad Jones
    Department of Immunology, University of Toronto, Toronto, ON, Canada
    J Exp Med 205:2763-79. 2008
    ..Blocking the Tim-3 signaling pathway restored proliferation and enhanced cytokine production in HIV-1-specific T cells. Thus, Tim-3 represents a novel target for the therapeutic reversal of HIV-1-associated T cell dysfunction...
  73. pmc Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis
    Martin W G Brinkhof
    Division of International and Environmental Health, Institute of Social and Preventive Medicine ISPM, University of Bern, Bern, Switzerland
    PLoS ONE 4:e5790. 2009
    ..The retention of patients in antiretroviral therapy (ART) programmes is an important issue in resource-limited settings. Loss to follow up can be substantial, but it is unclear what the outcomes are in patients who are lost to programmes...
  74. doi The costs and effectiveness of four HIV counseling and testing strategies in Uganda
    Nick Menzies
    US Centers for Disease Control and Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Atlanta, Georgia, USA
    AIDS 23:395-401. 2009
    ..HIV counseling and testing (HCT) is a key intervention for HIV/AIDS control, and new strategies have been developed for expanding coverage in developing countries. We compared costs and outcomes of four HCT strategies in Uganda...
  75. pmc A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells
    Nicolas Manel
    Molecular Pathogenesis Program, The Kimmel Center for Biology and Medicine of the Skirball Institute, New York University School of Medicine, New York, New York 10016, USA
    Nature 467:214-7. 2010
    ..The virulence of HIV-1 may be related to evasion of this response, the manipulation of which may be necessary to generate an effective HIV-1 vaccine...
  76. pmc Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
    ..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
  77. doi Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana
    Michael C Thigpen
    Division of HIV AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, USA
    N Engl J Med 367:423-34. 2012
    ..Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain...
  78. pmc Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals
    Davide Corti
    Institute for Research in Biomedicine, Bellinzona, Switzerland
    PLoS ONE 5:e8805. 2010
    ....
  79. pmc Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2
    C Celum
    Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave, Box 359927, Seattle, WA 98104, USA
    N Engl J Med 362:427-39. 2010
    ..Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1...
  80. pmc Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism
    Janet L Douglas
    Oregon Health and Science University, Vaccine and Gene Therapy Institute, Beaverton, 97006, USA
    J Virol 83:7931-47. 2009
    ..Understanding the molecular mechanisms of both Vpu-dependent and -independent mediated antagonism of BST-2 will be critical for therapeutic strategies that exploit this novel viral function...
  81. ncbi HIV infection and multidrug-resistant tuberculosis: the perfect storm
    Charles D Wells
    Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    J Infect Dis 196:S86-107. 2007
    ..The global human immunodeficiency virus (HIV) infection epidemic has caused explosive increases in TB incidence and may be contributing to increases in MDR-TB prevalence...
  82. pmc Common genetic variation and the control of HIV-1 in humans
    Jacques Fellay
    Center for Human Genome Variation, Duke Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, USA
    PLoS Genet 5:e1000791. 2009
    ..This study thus represents a comprehensive assessment of common human genetic variation in HIV-1 control in Caucasians...
  83. pmc Timing of initiation of antiretroviral drugs during tuberculosis therapy
    Salim S Abdool Karim
    Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa
    N Engl J Med 362:697-706. 2010
    ..The optimal timing for the initiation of antiretroviral therapy in relation to tuberculosis therapy remains controversial...
  84. pmc High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men
    Hui Li
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS Pathog 6:e1000890. 2010
    ....
  85. ncbi Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection
    Eberhard W Fiebig
    Department of Laboratory Medicine, University of California, San Francisco, CA, USA
    AIDS 17:1871-9. 2003
    ..The characterization of primary HIV infection by the analysis of serial plasma samples from newly infected persons using multiple standard viral assays...
  86. pmc The immune response during acute HIV-1 infection: clues for vaccine development
    Andrew J McMichael
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Nat Rev Immunol 10:11-23. 2010
    ..In this Review, we discuss recent studies on the kinetics and quality of early immune responses to HIV-1 and their implications for developing a successful preventive HIV-1 vaccine...
  87. pmc Projections of global mortality and burden of disease from 2002 to 2030
    Colin D Mathers
    Evidence and Information for Policy Cluster, World Health Organization, Geneva, Switzerland
    PLoS Med 3:e442. 2006
    ..This paper describes the methods, assumptions, input data, and results...
  88. ncbi Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    Punnee Pitisuttithum
    Department of Clinical Tropical Medicine, Mahidol University, Bangkok 10400, Thailand
    J Infect Dis 194:1661-71. 2006
    ....
  89. pmc Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes
    Margaret May
    Department of Social Medicine, University of Bristol, Bristol, UK
    Lancet 376:449-57. 2010
    ..We developed two prognostic models to estimate the probability of death in patients starting ART in sub-Saharan Africa...
  90. ncbi Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa
    Kristin L Dunkle
    Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA
    Lancet 363:1415-21. 2004
    ..No study on women has yet assessed gender-based violence as a risk factor for HIV after adjustment for women's own high-risk behaviours, although these are known to be associated with experience of violence...
  91. pmc The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
    Nilu Goonetilleke
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford OX3 9DS, England, UK
    J Exp Med 206:1253-72. 2009
    ..These included clusters of mutations in envelope that were targeted by NAbs, a few isolated sites that reverted to the consensus sequence, and bystander mutations in linkage with T cell-driven escape...
  92. pmc Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein
    Anna Le Tortorec
    Department of Infectious Disease, King s College London School of Medicine, Guy s Hospital, London SE1 9RT, United Kingdom
    J Virol 83:11966-78. 2009
    ..Finally, we recapitulated these observations in HIV-2-infected CD4+ T-cell lines, demonstrating that tetherin antagonism and sequestration occur at physiological levels of Env expression during virus replication...
  93. pmc Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1
    Richard E Haaland
    Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia, United States of America
    PLoS Pathog 5:e1000274. 2009
    ....
  94. ncbi Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings
    Bernard M Branson
    Division of HIV AIDS Prevention, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention proposed, Atlanta, GA 30333, USA
    MMWR Recomm Rep 55:1-17; quiz CE1-4. 2006
    ..Repeat screening in the third trimester is recommended in certain jurisdictions with elevated rates of HIV infection among pregnant women...
  95. pmc Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries
    Martin W G Brinkhof
    Institute of Social and Preventive Medicine, Bern, Switzerland
    Bull World Health Organ 86:559-67. 2008
    ..To analyse the early loss of patients to antiretroviral therapy (ART) programmes in resource-limited settings...
  96. pmc HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
    ..We assessed vaccine-induced immunity and its potential contributions to infection risk...
  97. doi HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells
    James Arthos
    Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Immunol 9:301-9. 2008
    ..On CD4+ T cells, engagement of alpha4beta7 by gp120 resulted in rapid activation of LFA-1, the central integrin involved in the establishment of virological synapses, which facilitate efficient cell-to-cell spreading of HIV-1...
  98. doi Providing universal access to antiretroviral therapy in Thyolo, Malawi through task shifting and decentralization of HIV/AIDS care
    Marielle Bemelmans
    Medecins Sans Frontieres, Blantyre, Malawi
    Trop Med Int Health 15:1413-20. 2010
    ..To describe how district-wide access to HIV/AIDS care was achieved and maintained in Thyolo District, Malawi...
  99. pmc Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo
    Nathalia Holt
    Keck School of Medicine of the University of Southern California, Los Angeles, California, USA
    Nat Biotechnol 28:839-47. 2010
    ..The demonstration that a minority of CCR5(-/-) HSPCs can populate an infected animal with HIV-1-resistant, CCR5(-/-) progeny supports the use of ZFN-modified autologous hematopoietic stem cells as a clinical approach to treating HIV-1...
  100. pmc Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance
    Chunlin Wang
    Division of Infectious Diseases, Department of Medicine, Stanford University, Stanford, CA 94305, USA
    Genome Res 17:1195-201. 2007
    ..With appropriate analysis, ultra-deep pyrosequencing is a promising method for characterizing genetic diversity and detecting minor yet clinically relevant variants in biological samples with complex genetic populations...

Research Grants100

  1. BRIEF HIV RISK REDUCTION COUNSELING
    Seth Kalichman; Fiscal Year: 2002
    ..Results of the proposed study will guide the allocation of HIV prevention resources in establishing brief and effective HIV risk reduction counseling services for populations vulnerable to HIV infection. ..
  2. BIOPTERIN, CATECHOLAMINES, & NO IN REGULATING APOPTOSIS
    Robert Levine; Fiscal Year: 2002
    ..These studies may will reveal novel apoptotic regulatory mechanisms and provide new avenues for therapeutic approaches to promote neuronal survival and prevent debilitating neurological diseases, such as Parkinson's disease. ..
  3. Preventing HIV and other STDs among drug-involved women
    Nabila El Bassel; Fiscal Year: 2005
    ..The SWRD Program will be directed by Dr. Nabila El-Bassel and co-directed by Drs. Steven Schinke and Mary McKay, all CUSSW faculty with strong programs of federally funded research related to substance abuse and HIV. ..
  4. HIV/STI Prevention for Drug-Involved Couples
    Louisa Gilbert; Fiscal Year: 2008
    ..Sharp from St. Luke's Hospital in New York City, and Dr. Fals-Stewart from the Research Institute on Addictions at the University of Buffalo. [unreadable] [unreadable] [unreadable]..
  5. PARTNER ABUSE AND HIV IN WOMEN RECEIVING EMERGENCY CARE
    Nabila El Bassel; Fiscal Year: 2002
    ....
  6. HIV Treatment Adherence/Risk Reduction Integrated
    Seth Kalichman; Fiscal Year: 2009
    ..If shown effective, the intervention model will have implications for community and clinical services for people living with HIV-AIDS. ..
  7. Intervention to Close Digital Divide in AIDS Care
    Seth Kalichman; Fiscal Year: 2004
    ..If successful, the experimental intervention could be readily implemented as a community-based program by AIDS Service Organizations, health centers, and community-based Internet access providers. ..
  8. Brief HIV Prevention Counseling in South Africa
    Seth Kalichman; Fiscal Year: 2009
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  9. Hepatoxicity in an African HIV Treatment Cohort
    Christopher Hoffmann; Fiscal Year: 2008
    ..It will be conducted within a large and on-going ARV cohort established as a collaborative project between a South African industrial conglomerate and Johns Hopkins University. [unreadable] [unreadable]..
  10. HIV TREATMENT ADHERENCE FOR PERSONS WITH LOW-LITERACY
    Seth Kalichman; Fiscal Year: 2002
    ..Results of the proposed research will provide critical information about improving HIV treatment adherence with low-literacy populations that is needed prior to conducting larger and more expensive clinical trials. ..
  11. Alcohol and HIV Risk Reduction in South Africa
    Seth Kalichman; Fiscal Year: 2006
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,500 new HIV infections in South Africa each day...
  12. Gender Violence and HIV Risk Reduction in South Africa
    Leickness Simbayi; Fiscal Year: 2007
    ..As many as one in five South Africans is HIV positive and there are an estimated 1,600 new HIV infections in South Africa each day...
  13. Enhancing HIV Medication Adherence in India
    DEBORAH LYNNE JONES; Fiscal Year: 2010
    ....
  14. Interventions to Enhance HIV Medication Adherence in Zambia
    Deborah Jones; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  15. TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
    Adeline Nyamathi; Fiscal Year: 2002
    ....
  16. Community-Based Approach to Designing an AIDS Program for HIV+ Mothers in India
    Adeline Nyamathi; Fiscal Year: 2008
    ..These findings will lead to future funding to actually develop and test a newly designed program. [unreadable] [unreadable] [unreadable]..
  17. Patterns and Contexts of Club Drug Abuse
    Jeffrey Parsons; Fiscal Year: 2007
    ..Mixed-methods strategies will be used to examine the qualitative and quantitative data together in order to further understand the data and potential implications for intervention development. ..
  18. Cervical Cancer Screening in HIV-infected women in India
    Sten Vermund; Fiscal Year: 2006
    ....
  19. Testing Primary HIV Infection in Seronegative Patients
    SPENCER BENNETT; Fiscal Year: 2005
    ..Abstract not provided ..
  20. Growth Hormone and Rosiglitazone for Visceral Adoposity
    Marshall Glesby; Fiscal Year: 2007
    ..If the results are as predicted, then combination therapy with rhGH and rosiglitazone may prove to be a highly effective treatment for visceral adiposity in HIV-infected patients. ..
  21. INDEPENDENT SCIENTIST AWARD
    Adaora Adimora; Fiscal Year: 2005
    ..Her training and experience have equipped her with uncommon insight into this problem. The K02 award will facilitate her accomplishing this career goal. ..
  22. Immunologic Control of Drug-resistant HIV-1
    Steven Deeks; Fiscal Year: 2005
    ..Finally, since we will estimate the relative in vivo thresholds for HIV-mediated immunogenicity and pathogenicity, these studies may also have implications for vaccine development. ..
  23. RCT of Russian IDU Peer Network HIV Prevent Intervention
    Carl Latkin; Fiscal Year: 2007
    Intravenous drug use (IDU) enables the HIV epidemic in Russia; over 90% of all HIV infections occur in communities of IDUs Russia and other countries where IDLJ is a major HIV transmission route need to identify low-cost, sustainable ..
  24. HIV Related Stigma among Service Providers in China
    Li Li; Fiscal Year: 2005
    ..These data will prepare the team to conduct a randomized controlled trial across different levels of health care providers in China. ..
  25. HIV Vaccine Trials in Women
    Beryl Koblin; Fiscal Year: 2006
    ..The primary outcomes to be compared are measures of unprotected sex and vaccine knowledge scores. ..
  26. Pathogenesis of Macrophage Tropic HIV-1
    Paul Gorry; Fiscal Year: 2004
    ..Understanding the molecular basis of enhanced M-tropism will provide further insights into HIV-1 pathogenesis, which is vital for the development of new inhibitors for the treatment of HIV-1 infection. ..
  27. The impact of early antiretroviral therapy on HIV persistence and inflammation
    STEVEN GRANT DEEKS; Fiscal Year: 2010
    ..Our work may also provide important insights in the role of chronic inflammation in driving viral persistence, and hence may lead to the development of novel interventions. ..
  28. Family-to-Family: Psychoeducation to Improve Children's Outcomes in HIV+ Families
    Li Li; Fiscal Year: 2009
    ..HIV+ parent's and family caregivers'health mental health, parenting skills, and family bonds are intermediate outcomes. ..
  29. Risk Reduction Intervention for Highly Vulnerable Emerging Adults Males
    Jeffrey T Parsons; Fiscal Year: 2010
    ..If effective, the intervention will help minimize the negative physical and psychological effects associated with club drug use, and reduce HIV infections among emerging adult males.
  30. ADHERENCE TO HAART IN THE CONTEXT OF DRUG ABUSE
    Glenn Wagner; Fiscal Year: 2001
    ..abstract_text> ..
  31. HIV Epidemiology Among African American Women in North Carolina
    Adaora Adimora; Fiscal Year: 2008
    ..abstract_text> ..
  32. North Carolina Needs Assessment for Oral Cancer Control
    Lauren Patton; Fiscal Year: 2003
    ....
  33. Measuring Incident Human Immonodeficiency Virus (HIV-1) Infections in China
    Sten Vermund; Fiscal Year: 2008
    ..Whether we pursue option 1 or 2 will depend upon the results of Specific Aim 1. Year two of this R03 award will be in the pursuit of option 1 or 2, as the science dictates. [unreadable] [unreadable] [unreadable]..
  34. Treatment Intensification for Drug-Resistant HIV
    Steven Deeks; Fiscal Year: 2004
    ..Funding for the pilot clinical trial has been obtained from other sources; funding is requested in this proposal only for costs associated with the measurements of immunologic response to drug-resistant HIV-1. ..
  35. National Survey on HIV Risk for African-American Women
    Gina Wingood; Fiscal Year: 2008
    ..2% of HIV infections from July 1999 through June 2000...
  36. High-Risk Heterosexual Partnering in the Age of AIDS: A Multilevel Analysis
    Adaora Adimora; Fiscal Year: 2008
    ..The study constitutes an important first step in development of future intervention studies and policies to effectively decrease the racial disparity in HIV infection rates. [unreadable] [unreadable] [unreadable]..
  37. THE LONG-TERM IMPACT OF A NETWORK OUTREACH INTERVENTION
    Carl Latkin; Fiscal Year: 2002
    ..The data will also used to examine associations between characteristics of sex partners and personal networks to describe sexual mixing patterns of this population. ..
  38. HIV Prevention and Adherence Intervention for HIV Positives and Partners in India
    CARL A contact LATKIN; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: This proposal has high public relevance due to the low rates of HIV medication adherence found in many impoverished communities domestically and internationally. ..
  39. Adherence Intervention for HIV + Alcohol Users
    Jeffrey Parsons; Fiscal Year: 2005
    ..Multivariate repeated measures analyses and growth curve modeling, using both continuous and dichotomous outcome variables, will be used to assess the impact of the intervention on both adherence and alcohol use. ..
  40. TEA for Families & Children: Preparation for a Randomized Trial
    Li Li; Fiscal Year: 2010
    ..The goal of this study is to develop and pilot an intervention for PLH and their family members in order to improve the long term health, mental health and behavioral adjustment of the children in poor, rural areas in China. ..
  41. A Network & Dyad HIV Prevention Intervention for Intravenous Drug User
    Carl Latkin; Fiscal Year: 2007
    ..Main outcome measures will be self-reported sex and injection risk behaviors. Self-reports will be cross-validated by urinalysis of STIs. [unreadable] [unreadable]..
  42. ENVIRONMENTAL AND MOLECULAR EPIDEMIOLOGY OF P CARINII
    Sten Vermund; Fiscal Year: 2001
    ..The long-term objective of this research is to prevent the transmission of PC in the health care as well as the home setting, thereby reducing the risk of PC infection among immunosuppressed individuals. ..
  43. Development and Evaluation of a Group HIV Intervention for Gender Stigmatized Per
    Jeffrey Parsons; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  44. Antidepressant & Behavioral Adherence Intervention for Depressed HIV Patients
    Glenn Wagner; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  45. Estimation Models for HIV/AIDS in China
    Sten Vermund; Fiscal Year: 2006
    ..We intend to use the findings to help the China CDC establishing a better estimation model for HIV/AIDS. [unreadable] [unreadable] [unreadable]..
  46. Network HIV Prevention Intervention for Drug Users
    Carl Latkin; Fiscal Year: 2006
    ..abstract_text> ..
  47. HIV Prevention, Cost-Utility Analysis and Race/Ethnicity
    Gina Wingood; Fiscal Year: 2004
    ..in order to make sound decisions about how to use available resources so as to maximize the number of HIV infections in various communities...
  48. NATIONAL STUDY OF SYRINGE EXCHANGE PROGRAMS
    Don Des Jarlais; Fiscal Year: 2003
    Many if not most of the new HIV infections in the US are occurring among intravenous drug users (IDUs) and their sexual partners...
  49. HIV RISK BEHAVIORS AMONG URBAN NOMAD DRUG INJECTORS
    Don Des Jarlais; Fiscal Year: 2003
    ..abstract_text> ..
  50. STARS: STUDENTS TALKING ABOUT REAL SOLUTIONS
    Gina Wingood; Fiscal Year: 2004
    ..The proposed study will examine the cost-effectiveness of the telephone relapse prevention condition relative to the group relapse prevention condition. ..
  51. SECONDARY PREVENTION AMONG HIV POSITIVE ALCOHOL ABUSERS
    Jeffrey Parsons; Fiscal Year: 2001
    ..Participants will complete assessment batteries at intake, and at 1-week, 3, 6, 9, and 12 month follow-ups in order to assess short-term and long-term effects. ..
  52. Life Projects and Antiretroviral Therapy: The Social Impacts of Scale-up
    Jennifer Hirsch; Fiscal Year: 2009
    ..abstract_text> ..
  53. Survival Signals in AIDS Lymphomas
    Ethel Cesarman; Fiscal Year: 2010
    ..Our data will help elucidate how best to inhibit EBV to improve the treatment of AIDS patients with lymphoma. ..
  54. Innovative Venue-Based Strategies to Identify STI Core Transmitters
    Jonathan Ellen; Fiscal Year: 2007
    ..We will also examine the electronic patient records of 1000 individuals, 18-35 years old, seeking GC/CT testing at the Baltimore City Health Department STI Clinic. [unreadable] [unreadable] [unreadable]..
  55. HHV8 ORF50 TRANSACTIVATOR
    Evelyn Quinlivan; Fiscal Year: 2001
    ..To identify expression of ORF50 in patients infected with HHV8. Results could be the basis for planning future studies of lytic gene expression, gene regulation and potential novel treatments of KS. ..
  56. KSHV TRANSFORMATION AND ANGIOGENESIS IN KAPOSIS SARCOMA
    Ethel Cesarman; Fiscal Year: 2001
    ..These studies will also provide information that will enrich our general knowledge of viral oncogenesis. ..
  57. DESIGN OF NOVEL IMMUNOGENS AND ADJUVANTS FOR HIV VACCINE
    Barton Haynes; Fiscal Year: 2003
    ..abstract_text> ..
  58. Adapting CHAMP+ for South Africa: Supporting HIV-Infected Youth and Families
    Claude Mellins; Fiscal Year: 2008
    ..The findings can be used to inform larger-scale effectiveness studies in similar settings. [unreadable] [unreadable] [unreadable]..
  59. Reduce Transmission Risks & Improve HCV Treatment Access
    Steffanie Strathdee; Fiscal Year: 2004
    ....
  60. Measuring Oral Disease Burden for Planning Services
    Michael Ross; Fiscal Year: 2003
    ..The principal investigator is based in Houston, Texas (USA) and the collaborators are based in Cape Town (South Africa), Dar es Salaam (Tanzania), and London (UK). ..
  61. RIBOZYMES AND RNA GENE THERAPIES FOR LIVER DISEASES
    Andrea Branch; Fiscal Year: 2003
    ..Northern analysis of RNAs extracted from serum samples of patients will establish the size distribution of HCV RNAs containing the terminal sequence. These studies will lead to new treatments for liver diseases. ..
  62. Training Program in Neurovirology
    HOWARD GENDELMAN; Fiscal Year: 2006
    ....
  63. CD8 LYMPHOCYTE RESPONSES IN SIV PATHOGENESIS
    JOERN SCHMITZ; Fiscal Year: 2004
    ..Determine the contribution of CD8+ lymphocytes to the loss of CD4+ Tcells following infection by SIVmac or the rapidly CD4+T cell-depleting virus SHIV-KB9. ..
  64. Rapid and Simple CSF Tests for Neurosyphillis Diagnosis
    Christina Marra; Fiscal Year: 2006
    ..The results of this study will be used to design field trials in the areas of greatest need. ..
  65. Human Papillovirus Testing in Adolescents
    Jessica Kahn; Fiscal Year: 2006
    ..Aim 5 To determine the cumulative prevalence and rates of persistence and regression of HPV infection, and correlation of HPV test results with cervicaI cytology, in the above sample of urban adolescent girls. ..
  66. Examining ART Adherence Issues in Bangalore India
    MARIA L EKSTRAND; Fiscal Year: 2010
    ....
  67. Immunopathogenesis of HIV-1 Infection: Role of Methamphetamine
    Madhavan P Nair; Fiscal Year: 2010
    ....
  68. HIV Intervention among Women at High Risk
    Xiushi Yang; Fiscal Year: 2010
    ..Findings will have far reaching implications for effective HIV prevention intervention among women at high risk in China. China's success will in turn be a key to global success in preventing the spread of HIV. ..
  69. CELL-MEDIATED IMMUNITY IN HEPATITIS C VIRUS INFECTION
    Bruce Walker; Fiscal Year: 2005
    ..abstract_text> ..
  70. Recovery & Help-Seeking Processes in Problem Drinkers
    JALIE TUCKER; Fiscal Year: 2009
    ..The proposed research appropriately models an "open economy" in which drinking problems are developed, maintained, and must be resolved. ..
  71. NEURONAL ELECTROPHYSIOLOGY IN HIV DEMENTIA
    HOWARD GENDELMAN; Fiscal Year: 2001
    ....
  72. HIV RISK AND PARTNER VIOLENCE--MEN ON METHADONE
    Nabila El Bassel; Fiscal Year: 2002
    ..Data from the proposed study will help inform assessment, treatment and referral protocols to reduce partner violence and HIV-risk behaviors among men and women in MMTPs. ..
  73. Anergizing effect of NK cell receptor expression on HIV-specific CD8+ T cells
    Galit Alter; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  74. beta-Amyloid Antibodies with Specific Proteolytic Activity
    Sudhir Paul; Fiscal Year: 2008
    ..Proteolytic anti-Abeta Abs capable of preventing the deposition of Abeta and cognitive decline would be candidates for passive immunotherapy of humans with AD. ..
  75. HIV/STD PREVENTION INTERVENTIONS FOR BLACK ADOLESCENTS
    JOHN JEMMOTT; Fiscal Year: 2003
    ..The results of this project will contribute to the development of effective HIV/STD risk-reduction programs for inner-city Black ..
  76. Case CFAR Meeting: HIV Pathogenesis
    Michael Lederman; Fiscal Year: 2006
    ..Presentation sessions will be Cellular Restrictions Factors; Latency; Protection from HIV Infection; Immune Pathogenesis; and Vaccines. ..
  77. REGULATING MITF'S ACTIVATION OF OSTEOCLAST TARGET GENES
    KIM MANSKY; Fiscal Year: 2007
    ..By understanding how Mitf activates ostoeclast specific genes, drug targets may be suggested that will lead to therapies to control the differentiation and activation of osteoclasts. [unreadable] [unreadable] [unreadable]..
  78. HIV PREVENTION TRIAL UNIT
    David Metzger; Fiscal Year: 2006
    ..Thus, an additional aim of our group is to be active participants in three of the PTN science working groups-Microbicides, Behavioral Intervention, and Substance Related Transmission. ..
  79. Topical Immune modulatory strategies to prevent HIV transmission
    Michael Lederman; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  80. 2007 Case CFAR Annual Spring Conference
    Michael Lederman; Fiscal Year: 2007
    ..The Case CFAR is proactive in its efforts to ensure inclusion of minority and female researchers in[unreadable] all aspects of Conference planning and attendance. ..
  81. HCV Treatment Cost-Effectiveness in 3 IDU Populations
    BRUCE SCHACKMAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  82. Anal Dysplasia in HIV+ and HIV- men
    Timothy Wilkin; Fiscal Year: 2006
    ..This study will help provide important new information on which groups of HIV+ men may benefit from screening and how HAART may modify this risk. ..
  83. Structure/Function Studies on Flavoproteins
    Irina Sevrioukova; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  84. Targeting Acute HIV
    Christopher Pilcher; Fiscal Year: 2007
    ..STAT provides for detection of very early acute HIV infections in this population by using novel specimen pooling and HIV RNA detection methods in a central State Laboratory ..
  85. Reducing HIV Risk among Mexican Youth
    Antonia Villarruel; Fiscal Year: 2005
    ....
  86. Simulation Tool for HIV/STD Cost-Effectiveness Analysis
    Steven Pinkerton; Fiscal Year: 2006
    ..abstract_text> ..
  87. Helminth infection and the risk of tuberculosis in children
    MOLLY FRANKE; Fiscal Year: 2007
    ..In both studies we will measure parasite burden and compare serum IgE levels in these two groups. Cases will be matched to controls by age, neighborhood, and TB contact history. [unreadable] [unreadable] [unreadable]..
  88. Rapid Responses to Problem Drinking on College Campuses
    SCOTT RHODES; Fiscal Year: 2007
    ..Although the environmental intervention should be more than one year, the minimum time would be one academic year with a one year follow up. A pilot study with a historically black college or university is also proposed. ..
  89. Amnis ImageStream Cell Analysis System
    Patricia Fitzgerald Bocarsly; Fiscal Year: 2007
    ..Instrument time may be made available to non-UMDNJ investigators from time-to-time when the ImageStream is not otherwise being used. [unreadable] [unreadable] [unreadable]..
  90. MIDCAREER INVESTIGATOR AWARD IN NEURO-AIDS RESEARCH
    David Simpson; Fiscal Year: 2005
    ..The Neuro-Adherence Program will assess the affect of neurological disease on patients' adherence to medical regimens, and the impact of education and support groups on adherence. ..
  91. A randomized trial of HAART in acute/early HIV Infection
    Joseph Margolick; Fiscal Year: 2008
    ..Comparison with untreated subjects carrying susceptible isolates will allow us to evaluate the contribution (positive or negative) of primary drug resistance on HIV disease progression. ..
  92. C-CAPRELA: Cervical Cancer Prevention for Latinas
    SCOTT RHODES; Fiscal Year: 2008
    ..developing effective interventions to reduce those disparities, and facilitating intervention delivery." [unreadable] [unreadable] [unreadable]..
  93. Gender,Migration,and HIV Risk among Hispanics:A Tri-National Study
    EMILIO PARRADO; Fiscal Year: 2008
    ..Findings from the study will provide culturally grounded and reliable information on gender, migration, and sexual behavior vital for the development of successful HIV interventions targeting Hispanic groups. ..
  94. STDS, FERTILITY, MARRIAGE AND DEMOGRAPHIC PROJECTION
    Ronald Gray; Fiscal Year: 2002
    ..In collaboration with the U.S. Bureau of Census, data from the proposed study will be used to revise demographic projections of the effects of HIV on population growth, composition and AIDS orphanhood. ..
  95. HIV Neuroprotection Workshop
    Joseph Berger; Fiscal Year: 2004
    ..The proposed conference is the first of its kind to highlight neuroprotection in HIV CNS and PNS disorders. By coupling this meeting with the International Symposium on Neurovirology this synergy can be exploited. ..